Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Negative equity NBB
More debt than assets in 3 of the last 4 fiscal years.
-
Two loss years in a row NBB
Negative result in 2023 and 2024.
-
Figures corrected NBB
Corrected annual account filed for 2024.
Financials
Financial year 2024
CENTRE SPECIALITES PHARMACEUTIQUES BENELUX from La Louvière, company number BE0897642057, closed financial year 2024 with a result of € -94,614 after tax. For that financial year CENTRE SPECIALITES PHARMACEUTIQUES BENELUX recorded revenue of € 11 million and equity of € -1.7 million. Compared with financial year 2023, the result moved from € -762,696 to € -94,614. The company made a loss. More debts than assets. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on November 3, 2025.
€ -1.7 million
▼ € 94,614 vs 2023
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -94,614
▲ 88 % less loss than in 2023
Profit after tax over the fiscal year.
€ 22.4 million
▲ 42% vs 2023
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € -2.7 million.
People and assets in 2024
54
▲ 2.8 vs 2023
Average over the fiscal year, from the social balance sheet.
€ 3.1 million
▲ 8% vs 2023
€ 57,000 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 90,078
▼ 1% vs 2023
Book value of vehicles, furniture and equipment.
Debts at end 2024
None
No bank loans on the last day of the fiscal year.
€ 4.7 million
▲ 31% vs 2023
Supplier invoices still open on the last day of the fiscal year. Pays suppliers within 221 days on average.
€ 1.6 million
▲ 11% vs 2023
Taxes, VAT and social contributions still to pay.
| 2021 | 2022 | 2023 | 2024 | Change 2023 → 2024 | |
|---|---|---|---|---|---|
| Revenue | € 12,987,616 | € 8,445,251 | € 9,858,198 | € 10,983,480 | ▲ 11% |
| Profit after taxes | € -375,579 | € -1,648,839 | € -762,696 | € -94,614 | ▲ € 668,082 |
| Equity | € 816,525 | € -832,314 | € -1,595,010 | € -1,689,625 | ▼ € 94,614 |
| Total debts | € 16,552,674 | € 19,457,556 | € 22,544,097 | € 30,623,669 | ▲ 36% |
| Cash | € 13,905,893 | € 14,797,509 | € 15,739,476 | € 22,406,265 | ▲ 42% |
| Land & buildings | € 4,699 | € 100,961 | € 203,522 | € 190,194 | ▼ 7% |
| Retained profit | € -231,975 | € -1,880,814 | € -2,643,510 | € -2,738,125 | ▼ € 94,614 |
| Bank debt | € 580,832 | € 92,124 | € 40,207 | € 0 | ▼ 100% |
| Balance sheet total | € 17,369,198 | € 18,625,241 | € 20,949,087 | € 28,934,044 | ▲ 38% |
| Employees (FTE) | 41.4 | 43.8 | 51.2 | 54 | ▲ 2.8 |
By revenue, CENTRE SPECIALITES PHARMACEUTIQUES BENELUX ranks 4th of 5 companies with main activity “Activiteiten van verpakkingsbedrijven” in Hainaut that publish figures (fiscal year 2024).
Key figures of CENTRE SPECIALITES PHARMACEUTIQUES BENELUX, fiscal years 2021 to 2024, from the annual accounts filed with the National Bank of Belgium.The annual account for fiscal year 2025 has not been filed yet; it was expected before 31 July 2026.
Ask about CENTRE SPECIALITES PHARMACEUTIQUES BENELUX the way you would ask their accountant.
Answers from the filed annual accounts, the Belgian Official Gazette and the CBE register.
Connect ChatGPT or Claude for free- ChatGPT
- Claude
Free account, no payment card. Key figures unlimited, the annual accounts and deeds of 10 companies a month. Need more? Get in touch, we are looking for our first pilot users.
What happened to CENTRE SPECIALITES PHARMACEUTIQUES BENELUX?
What happened at CENTRE SPECIALITES PHARMACEUTIQUES BENELUX in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- Corrected annual accounts filed for financial year 2024. filed late Source: NBB ↗
- Capital increase of € 1.5 million, published in the Gazette. Source: Staatsblad ↗
- PATRICK VERKUIJLEN became a director. NBB
- THOMAS CREUZBERGER became a director. NBB
- Incorporation, published in the Gazette. Source: Staatsblad ↗
- New establishment in La Louvière. KBO
In short
From € 375,579 loss in 2021 to € 94,614 loss in 2024.
Paid € 52,001 in corporate taxes since 2021.
Management
Behind CENTRE SPECIALITES PHARMACEUTIQUES BENELUX are PATRICK VERKUIJLEN and THOMAS CREUZBERGER. The shares are held by CENTRE SPECIALITES PHARMACEUTIQUES S. Etr. (100%).
Directors
According to the 2024 annual accounts
PATRICK VERKUIJLEN
Director
since 2020
THOMAS CREUZBERGER
Director
since 2020
Shareholders
CENTRE SPECIALITES PHARMACEUTIQUES S. Etr.
100%
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Chemin de la Reconversion(H-G) 17-19
7110 La Louvière
Chemin de la Reconversion(H-G) 19
7110 La Louvière
Active since 28 April 2008
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Similar companies in Hainaut
Same main activity (Activiteiten van verpakkingsbedrijven), 29 active companies in Hainaut, largest first.
€ 20.6 million revenue · 2024 · Charleroi
€ 20.3 million revenue · 2025 · Seneffe
€ 18.4 million revenue · 2025 · Fleurus
€ 4 million gross margin · 2025 · Binche
€ 3.8 million gross margin · 2025 · Ath
€ 3.5 million gross margin · 2025 · Ecaussinnes
Shareholders according to the Official Gazette deeds
Who contributed at incorporation and at capital increases, with the deed as source. Later share transfers are not published in the Gazette.
Incorporation
Source: Deed ↗- CENTRE SPÉCIALITÉS PHARMACEUTIQUES S.A.(fondateur) 100%
Details
- Company number
- 0897.642.057
- VAT number
- BE 0897.642.057
- Registered office
- Chemin de la Reconversion(H-G) 17-19, 7110 La Louvière
- Names & denominations
- CENTRE SPECIALITES PHARMACEUTIQUES BENELUX · CSP BENELUX
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 28 April 2008
- Peppol
- Active · Active since 21 Oct 2026
- Activities · NACE
Activiteiten van verpakkingsbedrijven
Opslag
Vervaardiging van andere voedingsmiddelen, neg
Vervaardiging van geneesmiddelen
Groothandel in farmaceutische en medische artikelen
Groothandel in andere voedingsmiddelen, neg
Overige zakelijke dienstverlening, neg
Vervaardiging van farmaceutische grondstoffen
+5